












doi:10.101Host Basophils Are Dispensable for Induction of Donor
T Helper 2 Cell Differentiation and Severity of
Experimental Graft-versus-Host Disease
Isao Tawara,1 Evelyn Nieves,1 Chen Liu,2 Rebecca Evers,1 Tomomi Toubai,1 Yaping Sun,1
Mariem Alrubaie,1 Pavan Reddy1Host hematopoietic-derived antigen-presenting cells are important for induction of graft-versus-host disease
(GVHD). The relative importance of various subsets of hematopoietic-derived antigen-presenting cells is not
well understood. Recent data suggest that basophils can function as antigen-presenting cells and induce
T helper 2 (Th2) lymphocyte responses. We investigated the role of host basophils in the induction of donor
T cell responses and GVHD after allogeneic bone marrow transplantation. Elimination of host basophils did
not alter the severity of GVHD-induced mortality across multiple clinically relevant models of allogeneic
bone marrow transplantation. Furthermore, induction of donor T cell proliferation and Th2 polarization
was not altered significantly after depletion of host basophils. Our results demonstrate that, in contrast
to their role in inducing Th2 responses in certain contexts, basophils are dispensable for the induction of
donor Th2 responses and for the severity of GVHD.
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Basophils, basophilic granulocytes circulating in
the peripheral blood, account for\1% of blood leuko-
cytes and share certain features with mast cells [1].
Given their smaller numbers and shorter life span, ba-
sophils traditionally have been considered of minor
relevance compared with mast cells [2,3]. However,
exciting recent data have demonstrated that basophils
play a significant role on their own [3,4]. Basophils
have been shown to provide IL-4 and present antigens
to na€ıve T cells [5-8]. Several studies have suggested
that basophils can act as potent antigen-presenting
cells (APCs) and are necessary and sufficient for the
induction of T helper (Th) 2 cell responses [8-13].e 1Department of Internal Medicine, Blood and
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notion of the ability of basophils to prime Th2 cell
responses, the importance of basophils in allogeneic
T cell responses is unclear [14-16]. Specifically, the
role of basophils in modulating alloantigen-driven
Th cell differentiation and in vivo alloresponses, such
as graft-versus-host disease (GVHD), is not known.
Host hematopoietic-derived APCs play an impor-
tant role in the induction of host alloantigen-driven
donor T cell responses leading to GVHD [17]. Allor-
eactive cytopathic donor T cells, when presented by
alloantigens in the proper context, proliferate, differen-
tiate intoTh1/Th2/Th17 effector cells, and cause target
organ damage [18-21]. Although the exact and specific
roles of different Th cell subsets in causing GVHD
are complex and well studied [22], the roles of host
hematopoietic-derived APCs in Th cell differentiation
after allogeneic bone marrow (BM) transplantation
(BMT) are not well understood. Furthermore, the
importance of different host hematopoietic-derived
APC subsets in causing GVHD remains unclear [22].
We investigated the contribution of host basophils in
the presence of other APCs to inducing donorT cell po-
larization andGVHD severity.Usingmultiple clinically
relevantmurinemodels ofGVHD,we found that deple-
tion of host basophils did not alter theTh1/Th2 balance
of donor T cells or regulate the severity of GVHD after
allogeneic BMT.1747
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Mice
Female C57BL/6 (B6, H-2b, CD45.21) mice
were purchased from Charles River Laboratories
(Wilmington, MA). B6-Ly5.2/Cr (B6-CD45.1, H-2b,
CD45.11) mice were purchased from the National
Cancer Institute (Frederick, MD). BALB/c (H-2d,
CD45.21) and B6D2F1 (H-2b/d, CD45.21) mice
were purchased from Taconic (Hudson, NY).
B6.129S7-Ifngtm1TS/J (B6-background IFN-g-KO,
H-2b, CD45.21) mice were purchased from the
Jackson Laboratory (Bar Harbor, ME).
Cell Culture
For the generation of BM dendritic cells (DCs),
BM cells were harvested from tibias and femurs and
cultured for 7 days in RPMI 1640medium (Invitrogen,
Carlsbad, CA) supplemented with 10% FCS (Invitro-
gen) and 20 ng/mL recombinant murine granulocyte
macrophage-colony stimulating factor (GM-CSF)
(Peprotech, Rocky Hill, NJ) [23]. Samples were en-
riched for DCs by positive selection of CD11c1 cells
using MACS anti-CD11c microbeads and LS columns
(Miltenyi Biotec, Auburn, CA). For the generation of
BM basophils, BM cells were cultured for 9-10 days
in RPMI 1640 media supplemented with 10% FCS
and 10 ng/mL recombinant murine IL-3 (Peprotech)
[1,6,8,9]. Samples were enriched for basophils by
positive selection of DX51 cells using MACS DX5
microbeads and LS columns (Miltenyi Biotec).
Antibodies and Flow Cytometric Analysis
FITC-, PE-, PerCP-Cy5.52, or APC-conjugated
monoclonal antibodies (mAbs) to mouse CD4 (clone:
RM4-4), CD8a (53-6.7), CD45.1 (A20), CD45.2 (104),
CD49b (DX5), CD80 (16-10A1), CD86 (GL1), Fc 3R1
(MAR-1), H-2Kb (AF6-88.5.5.3), H-2Kd (SF1-1.1),
and I-A/I-E (M5/114.15.2) were purchased from eBio-
science (San Diego, CA). Anti-mouse CD40 (3/23),
I-Ab (AF6-120.1), and I-Ad (AMS-32.1) were purchased
from BD Pharmingen (San Diego, CA). Cultured BM
cells, spleen cells from mice that underwent BMT, and
peripheral blood cells frommAb-treatedmicewere incu-
bated with anti-CD16/CD32 (2.4G2; Fc block; BD
Pharmingen) mAb for 15 minutes at 4C in staining
buffer (2%FCS-containing PBS), then cells were stained
with fluorochrome-conjugated mAbs for 15 minutes at
4C in the staining buffer. After washing, the cells were
analyzed with a flow cytometer (model C6; Accuri Cy-
tometers, Ann Arbor, MI) [24]. Basophils were gated
for on SSClow cells as described previously [25].
Bone Marrow Transplantation
Host mice were irradiated (137Cs source) with 8-10
Gy of total body irradiation 1 day before BMT. DonorBM cells were harvested from femurs and tibias and
T cells in the BM were removed magnetically using
CD90.2 microbeads (Miltenyi Biotec) and MACS LS
columns (Miltenyi Biotec) [26]. Spleen T cells were
magnetically isolated using CD90.2 microbeads and
MACS LS columns (Miltenyi Biotec). T cell numbers
were determined based on cell count and purity. Syn-
geneic or allogeneic T cell–depleted BM (TCDBM)
and T cells were infused through tail veins [26]. For
basophil-depletion experiments, host mice were ip
treated with 10 mg of Fc 3RI mAb (MAR-1 functional
grade purified; eBioscience) on days -1, 0, and 1. Con-
trol group host mice were treated with 10 mg of Arme-
nian hamster IgG (functional grade purified;
eBioscience). Host mice were housed in sterilized mi-
croisolator cages and maintained on acidified water
(pH\3) for 3 weeks as described previously [26]. Sur-
vival was monitored daily and clinical GVHD was as-
sessed weekly, as described previously [26]. All animal
studies were performed in accordance with the guide-
lines of the University of Michigan’s Institutional An-
imal Care and Use Committee.
Cytokine Analysis
Levels of IFN-g, IL-4, IL-5, and IL-17A in sera
were determined by ELISA (BD Pharmingen) in
accordance with the manufacturer’s instructions.
Spleen cells harvested from BMT hosts were stimu-
lated with soluble anti-mouse CD3e mAb (2 mg/mL,
eBio500A2 functional grade purified; eBioscience)
and anti-mouse CD28 (2 mg/mL, 37.51 functional
grade purified; eBioscience) in the presence of brefel-
din A (1/1000 dilution; eBioscience) for 5 hours [24].
After stimulation, cell surface markers were stained
and fixed for 20 minutes with FACS lysing solution
(BD Bioscience, San Jose, CA) and processed for in-
tracellular cytokine staining. Fixed cells were washed
with permeabilization buffer (eBioscience) and
stained with PE-conjugated anti-mouse IFN-g
(XMG1.2; BD Pharmingen), APC-conjugated anti-
mouse IL-4 (11B11; eBioscience) or PE-conjugated
anti-mouse IL-17A (eBio17B7; eBioscience) for 30
minutes at 4C [24]. The cells were washed twice
with permeabilization buffer and staining buffer, re-
suspended with staining buffer, and analyzed with
the Accuri Cytometers C6 flow cytometer.
Histology
Formalin-preserved gut and liver were embedded
in paraffin, cut into 5-mm-thick sections, and stained
with hematoxylin and eosin for histological examina-
tion. Slides were coded without reference to previous
treatment and examined in a blinded fashion by a pa-
thologist (C. Liu). A semiquantitative scoring system
was used to assess the abnormalities known to be asso-
ciated with GVHD [27,28].
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The Student t test was used for the statistical anal-
ysis of in vitro data, and the Wilcoxon rank sum test
was used to analyze survival data. A P value\.05 was
considered statistically significant.RESULTS
Basophils Are Poor Stimulators of Allogeneic
T Cells
We evaluated the ability of basophils to stimulate
allogeneic T cells in vitro. We cultured BALB/c
T cells with basophils cultured from allogeneic B6
BM in a standard mixed leukocyte reaction assay.
The stimulatory capacity was compared with BM-
derived B6 DCs, the most potent APCs. As expected,
the B6 DCs caused robust proliferation of allogeneic
BALB/c T cells (Figure 1A). In contrast, as shown in
Figure 1A, B6 basophils caused significantly less pro-
liferation of allogeneic T cells (P\ .0001). Changing
the stimulator-to-responder ratio did not alter the in-
ability of basophils to stimulate allogeneic T cells. To
rule out any strain-dependent effects, we also tested
the ability of BALB/c DCs and basophils to stimulate
B6 T cells in a mixed leukocyte reaction assay. BALB/
c-derived basophils also demonstrated poor ability to
stimulate proliferation of allogeneic B6 T cells com-
pared with DCs (Figure 1B).
We next analyzed the phenotype of the BM-
derived basophils and compared it with the BM
DCs from B6 animals. As shown in Figure 1C,
BM-derived basophils demonstrated significantly
lower expression of MHC class II, CD80, CD86,
and CD40 cells compared with BM DCs. Similarly,
BM-derived basophils from BALB/c demonstrated
lower expression of MHC class II and CD80,
CD86, and CD40 cells compared with BALB/c BM
DCs, thus ruling out potential strain-dependent arti-
facts (Figure 1C). These data suggest that basophils
are poor in vitro APCs for stimulation of allogeneic
T cells due to inappropriate expression levels of cos-
timulatory molecules.
Host Basophils Do Not Alter in Vivo Generation
of Allogeneic Th2 Polarization
To examine whether basophils are critical for in-
duction of in vivo allogeneic donor T cell responses,
we used the BALB/c (H-2d)/B6 (H-2b) mouse model
of allogeneic BMT. The B6 recipients were injected
with MAR-1 (Fc 31) or control IgG on days -1, 0, and
1 to eliminate host basophils, as described in Materials
and Methods. This schedule was chosen based on pre-
vious reports and successfully depleted basophils in the
BM and spleen regardless of irradiation (Figure 1D)
[7,8,10,11]. Nonetheless, this schedule could possiblydeplete the early-engrafting basophils from the infused
TCDBM. The B6 animals were lethally irradiated and
underwent transplantation with TCDBM and na€ıve
splenic T cells from allogeneic (BALB/c) or syngeneic
(B6) donors on day 0. Donor T cell expansion and dif-
ferentiation were analyzed in the spleen on day17 after
allogeneic BMT. As shown in Figure 2A, allogeneic
BALB/c donor T cells demonstrated equivalent expan-
sion and also similar levels of IFN-g1 (Th1), IL-41
(Th2), and IL-17A1 (Th17) regardless of depletion of
the basophils in the B6 hosts. Furthermore, consistent
with expansion of the Th1, Th2, andTh17 cells, deple-
tion of basophils had no statistically significant impact
on serum levels of IFN-g, IL-4/IL-5, and
IL-17A.
Because of the potential for strain-dependent differ-
ential effects on T cell polarization, we examined the
effect of basophil depletion on allogeneic T cell expan-
sion and Th cell differentiation in a second, clinically
relevant, B6 (H-2b)/B6D2F1 (H-2b/d) model of allo-
geneic BMT [29]. The B6D2F1 animals were injected
with MAR-1 (Fc 31) or control IgG and then used as
recipients of allogeneic BMT. As shown in Figure 2B,
B6 donor T cells demonstrated similar expansions of
Th1 and Th2 cells (P 5 not significant [NS]) but
greater expansion of Th17 cells (P 5 .023) in the
basophil-depletedmice comparedwith control animals.
Serum levels of IFN-g, IL-4, and IL-17A were similar
in the 2 groups (P 5 NS), although the serum level of
IL-5 was decreased in the basophil-depleted group
(P 5 .006). In contrast, donor T cells from the na€ıve,
nontransplanted BALB/c and B6mice did not constitu-
tively demonstrate any significant numbers of either
Th1 (IFN-g), Th2 (IL-4), or Th17 (IL-17A) cells.
These data collectively demonstrate that host basophils
are not required for in vivo expansion and Th2 polari-
zation of allogeneic T cells.
Host Basophils Are Dispensable for Induction
of Mortality From GVHD
Host APCs are critical for induction of GVHD [30-
32]. The relative roles of various host hematopoietic-
derived host APC subsets in causing GVHD are not
well understood. We therefore examined whether host
basophils modulate the severity of GVHD. Even
though depletion of host basophils did not alter the
expansion or Th polarization of donor T cells, it
is formally possible that they might modulate the
severity of distinct target organs [21]. Thus, using the
BALB/c/B6 model, we analyzed whether depletion
of host basophils differentially affected the pathology
of GVHD-specific target organs, the gastrointestinal
tract, liver, and skin. The target organs from the alloge-
neic animals were harvested on day 17 after BMT and
analyzed for histopathological severity. Elimination of
host basophils enhanced the histopathological severity
in the large and small intestines (P\ .05) but not in
Figure 1. Basophils are poor stimulators of allogeneic T cells. (A) Indicated numbers of in vitro IL-3–induced BM B6 basophils (DX51) or GM-CSF–in-
duced BMDCs (CD11c1) and 4 104 BALB/cCD901T cells were cocultured in a 96-well round-bottomed plate for 5 days. Incorporation of 3H-thymidine
(1 mCi/well) by proliferating cells during the last 6 hours of culture was measured. (B) Indicated numbers of in vitro IL-3–induced BALB/c BM basophils
(DX51) orGM-CSF–inducedBMDCs (CD11c1) and4104 B6CD901Tcellswere cocultured in a 96-well round-bottomedplate for 5 days. Incorporation
of 3H-thymidine (1mCi/well) byproliferating cells during the last 6 hoursof culturewasmeasured. (C) Flowcytometric analysis of B6 andBALB/cBMDCs and
basophils. MHC class II (I-Ab for B6; I-Ad/I-Ed for BALB/c), CD40, CD80, and CD86 expression levels on CD11c1 cells (DCs, top row) andDX51 cells (ba-
sophils; bottom row) are shown. The numbers shown in the histograms indicate the percent positivity of the surfacemarker. (D) Flow cytometric analysis of
control hamster mAb-treated (left) or MAR-1–treated (right) BALB/c mouse peripheral blood. Mice were treated with 10 mg of control mAb or MAR-1 3
times every 24 hours, and peripheral blood samples were corrected from the mice and analyzed. The numbers in the dot plots indicate the percentages of
DX51Fc 3RI1 cells.
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skin changes were observed (data not shown).
We next evaluated the effects of basophil deple-
tion on the clinical severity and mortality of acute
GVHD. Basophil depletion demonstrated no signif-
icant impact on survival, GVHD severity, or body
weight after allogeneic BMT (Figure 3B; P 5 NS).
All surviving mice showed greater complete donor
chimerism by fluorescence-activated cell sorter anal-ysis (data not shown), ruling out graft failure or
mixed chimerism as a cause for GVHD.
To rule out strain-dependent artifacts, we also
examined the impact of host basophil depletion on
GVHD severity in the B6/B6D2F1 model of alloge-
neic BMT [29]. The B6D2F1 recipients demonstrated
similar target organ histopathology, clinical severity of
GVHD, and weight loss after allogeneic BMT
(Figure 3C; P 5NS). A similar lack of impact was
Figure 2. Effect of basophil depletion on donor T cell expansion and cytokine production. (A) B6-CD45.1 (CD45.11, CD45.22) recipients were ir-
radiated (10 Gy) on day 21 and injected with 5  106 BALB/c (CD45.21) TCDBM and 4  106 CD901 T cells on day 0. Recipients were treated
with 10 mg of hamster IgG (control Ab) (-; n5 4) or anti-mouse Fc 3RI (MAR-1) (,; n5 4) on days21, 0, and 1. Spleen cells and sera were collected
from recipients on day 7. Spleen cells were counted; stained with anti-CD45.2, -CD4, and -CD8mAbs; and analyzed by flow cytometry. Donor CD4 and
CD8 T cell expansion was determined based on donor marker (CD45.2), CD4, and CD8 positivity. Intracellular IFN-g, IL-4, and IL-17A staining was
performed after stimulation of spleen cells with anti-CD3 3and anti-CD28mAbs. Numbers of cytokine-producing cells were determined based on donor
marker and cytokine positivity. Serum cytokine levels were determined by ELISA. B, B6D2F1 (CD45.12, CD45.21) recipients were irradiated (10 Gy)
on day 21 and injected with 5  106 B6 (CD45.12, CD45.21) TCDBM and 2  106 B6-CD45.1 (CD45.11, CD45.22) CD901 T cells on day 0. Re-
cipients were treated with 10 mg of control Ab (-; n 5 4) or MAR21 (,; n 5 4) on days 21, 0, and 1. Spleen cells and sera were collected from
recipients on day 7. Spleen cells were counted; stained with anti-CD45.1, -CD4, and -CD8 mAbs; and analyzed by flow cytometry. Donor CD4 and
CD8 T cell expansion was determined based on donor marker (CD45.1), CD4, and CD8 positivity. Intracellular IFN-g, IL-4, and IL-17A staining
was performed after stimulation of spleen cells with anti-CD3 3and anti-CD28 mAbs. Numbers of cytokine-producing cells were determined based
on donor marker and cytokine positivity. Serum cytokine levels were determined by ELISA.
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logeneic BMT (Figure 3D; P 5 NS). Given that the
absence of Th1 polarization has been suggested to en-
hance Th2 polarization, we also examined the impact
of depletion of host basophils on INF-g–deficient
T cell polarization and GVHD severity after alloge-
neic BMT. Depletion of host basophils did not modu-
late T cell polarization of GVHD severity despite the
absence of Th1 (INF-g) secretion by themature donor
T cells (Figure 3E; P 5 NS). Collectively, these data
demonstrate that host basophils do not play a signifi-
cant role in the induction and severity of GVHD.DISCUSSION
Recent data have brought into focus the role of baso-
phils as APCs and in priming Th2 responses [3,4,8-13].
How basophils act in Th2 polarization and regulation of
in vivo allogeneic responses is not known. Because host
hematopoietic-derived APC subsets are important for
priming donor T cells after allogeneic BMT, we tested
the hypothesis that depletion of host basophils will
reduce Th2 polarization (and enhance Th1 and Th17
polarization) and modulate GVHD [30,31]. Indisagreement with our hypothesis, we found that host
basophils were dispensable both for priming of Th2
responses and for modulating the severity of GVHD
after allogeneic BMT. The lack of impact of basophil
depletion was observed in multiple models of
allogeneic BMT, thus ruling out strain-dependent arti-
facts. This is in contrast to the recent reports demon-
strating in distinct experimental settings that basophils,
rather than DCs, are the critical APCs driving Th2 cell
differentiation [8-11,13]. In immunization models with
protease allergens mediated by IgE or with parasite
Trichuris muris, depletion of basophils as performed in
our experiments (by pretreatment with theMAR-1 anti-
body to Fc 3RI) led to the loss of Th2 differentiation [8-
13]. The APC function and induction of
Th2 responses were critically dependent on the
interaction of MCH class II on basophils with the
CD41 T cells [8,10]. Our data demonstrate that
although basophils constitutively express MHC class
II and other conventional costimulatory molecules,
such as CD80, CD86, and CD40, the level of
expression of these molecules are much lower than in
conventional DCs. Furthermore, in vitro studies also
demonstrated that basophils are less effective than
DCs in priming allogeneic T cell responses. Thus, in
Figure 3. Effect of basophil depletion onGVHDseverity. (A) B6-CD45.1
recipients were irradiated (10 Gy) on day 21 and injected with 5  106
BALB/c (CD45.21) TCDBM and 4 106 CD901 T cells on day 0. Recip-
ients were treated with 10 mg of control Ab (-; n54) or MAR-1 (,; n
54) on days21, 0, and 1. GVHD target organs (small and large intestines
and liver) were removed on day 7 for pathological analysis. GVHD pathol-
ogy scores are shown. (B) B6 recipients were irradiated (10 Gy) on day
21 and injectedwith 5 106 syngeneic B6 TCDBM (; n5 6). Allogeneic
BMT recipients were treated with 10 mg of control Ab (; n 5 10) or
MAR-1 (B; n 5 10) on days -1, 0, and 1 and then injected with 5 
106 BALB/c TCDBM and 4 106 CD901 T cells. Survival was monitored
daily, and GVHD clinical score and body weight changes were monitored
weekly. (C) B6D2F1 recipients were irradiated (10 Gy) on day21 and re-
ceived 5  106 syngeneic B6 TCDBM (; n 5 6), Allogeneic BMTrecip-
ientswere treated with 10 mg of control Ab (; n5 8) orMAR-1 (B; n5
8) on days21, 0, and 1, and injected with 5 106 B6 TCDBM and 2 106
CD901 T cells. Survival wasmonitored daily, andGVHDclinical score and
bodyweight changes weremonitoredweekly. (D) BALB/c recipients were
irradiated (8 Gy) on day 21 and received 5  106 syngeneic BALB/c
TCDBM (; n 5 7). Allogeneic BMT recipients were treated with 10
mg of control Ab (; n 5 8) or MAR-1 (B; n 5 8) on days 21, 0, and
1, and injected with 5  106 B6 TCDBM and 0.5  106 CD901 T cells.
Survival was monitored daily, and GVHD clinical score and body weight
changes were monitored weekly. (E) B6D2F1 recipients treated with 10
mg of control Ab (A; n 5 8; days 21, 0, and 1) or MAR-1 (>; n 5 8;
days 21, 0, and 1) were irradiated (10 Gy) on day 21 and injected with
5  106 wild-type B6 TCDBM and 2  106 IFN-g-KO CD901 T cells
on day 0. Survival was monitored daily. P 5 NS.
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basophils are poor inducers of T cell proliferation
and are dispensable for Th2 priming in the context
of in vivo allogeneic responses.
Our results are consistent with the previous obser-
vations of only a minor role for basophils as APCs and
Th2 inducers [13-16]. Hammad et al. [14] reported
that the Fc 3RIa mAb (MAR-1) efficiently depletes
not only basophils, but also a subset of DCs that ex-press Fc 3RI. Our data suggest that these DC subsets,
in addition to the basophils, also might be dispensable
for Th2 differentiation after allogeneic BMT, and thus
basophils are not potent or the primary inducers of
Th2 polarization in the context of allogeneic stimula-
tion. Therefore, the relative contribution of basophils
and DCs to in vivo Th2 differentiation may depend on
the type of model and the stimulus.
Consequently, in the context of allogeneic BMT,
host basophils have no significant impact on the sever-
ity of GVHD mortality. After allogeneic BMT, other
host APCs might be sufficient to drive Th2 differenti-
ation, due perhaps to the presence of the right cytokine
milieu from the conditioning and the allogeneic T cell
responses. We did not directly address the role of do-
nor BM-derived basophils, which may play a role in
maintaining the Th2 phenotype of donor T cells. Ba-
sophils have an estimated in vivo life span of only 60
hours and are very fragile cells with poor survival after
standard sorting procedures [1-3,5]. Thus, performing
transfer experiments with basophils is technically
challenging. Nonetheless, it is important to point out
that our observations do not negate a critical role for
basophils in the maintenance of alloantigen-driven
Th2 and memory responses, either alone or in concert
with other accessory cells or APCs [33]. Alternatively,
in the context of alloresponses, at least in vivo, DCs
and other APCs likely dominate the alloantigen
presentation and donor T cell responses. Thus, it is
possible that basophils might target different types of
antigens and lead to subsequent generation of Th2
responses, even though they are poor presenters of
alloantigens.
Both host and donor hematopoietic-derived APCs
play a role in GVHD [32,34-36]. Host hematopoietic-
derived APCs have been shown to be crucial for
induction of graft-versus-host responses [30,31].
Nonetheless, the role of specific host hematopoietic-
derived APC subsets remains unclear. Emerging data
suggest a role for DCs in the absence of all other
APCs, but whether DCs are necessary in the presence
of other APC subsets is not known [37-39]. Host B
cells have been shown either to be dispensable for
induction of GVHD or to exert a regulatory effect on
the severity of GVHD [39,40].Murphy et al. [41] dem-
onstrated that hostmast cellsmay play a role in enhanc-
ing skin GVHD. Although basophils share many
similarities with mast cells, they differ in several ways;
for example, mast cells have a longer half-life than ba-
sophils, reside primarily in peripheral tissues, and can
proliferate even after maturation [1,3]. Thus, whereas
host mast cells may be critical for modulating
GVHD target organ damage, host basophils do not
play a significant role in either enhancing or
mitigating GVHD-specific target organ damage.
In summary, we have demonstrated that host baso-
phils are dispensable for the induction of Th2 cell
Biol Blood Marrow Transplant 17:1747-1753, 2011 1753Basophils & GVHDdifferentiation in the context of allogeneic stimulation.
Although the roles of Th1/Th2/Th17 effector path-
ways in affecting the type, severity, and specificity of
GVHD are complex and incompletely understood,
our data suggest that targeting host basophils will
not mitigate mortality from GVHD.ACKNOWLEDGMENTS
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